ExonHit Extends License for Ariadne's Pathway Software | GenomeWeb
NEW YORK (GenomeWeb News) - ExonHit Therapeutics has extended its license for Ariadne’s Pathway Studio software for its research projects in alternative RNA splicing, Ariadne said today.
Under the agreement, ExonHit will continue to use Pathway Studio in collaborations with drug development partners.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.